Meet Janet Tu, M.D.
Janet Tu, MD
Department of General Oncology, Division of Cancer Medicine
About Dr. Tu
Janet Tu did her undergraduate work at Rice University in Houston, Texas and received her Bachelor of Arts degree in Biochemistry. Afterwards, Dr. Tu received her Doctor of Medicine degree from Baylor College of Medicine followed by completion of Internal Medicine Residency at Baylor College of Medicine. She went on to complete Hematology-Oncology Fellowship program at Baylor Colllege of Medicine. Dr. Janet Tu became board certified in Hematology and Medical Oncology upon completion of fellowship and has served as full time faculty at the University of Texas M.D. Anderson Cancer Center since 2009.
Read More
Present Title & Affiliation
Primary Appointment
Professor, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Department of Thoracic, Head, and Neck Medical Oncology (Joint Appointment), The University of Texas MD Anderson Cancer Center, Houston, Texas
Dual/Joint/Adjunct Appointment
Professor, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 1999 | Baylor College of Medicine, Houston, Texas, US, Doctor of Medicine |
| 1995 | Rice University, Houston, Texas, US, Bachelor of Arts in Biochemistry |
Postgraduate Training
| 2006-2009 | Clinical Fellowship, Hematology/Medical Oncology, Baylor College of Medicine, Houston, Texas |
| 1999-2002 | Clinical Residency, Internal Medicine, Baylor College of Medicine, Houston, Texas |
Board Certifications
| 2002 | American Board of Internal Medicine |
Experience & Service
Academic Appointments
Associate Professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2020 - 2023
Associate Professor, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2017 - 2023
Assistant Professor, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2009 - 2017
Administrative Appointments/Responsibilities
Houston Area Location Section Chief, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2019 - Present
Deputy Department Chair, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2019 - Present
Houston Area Location Sugar Land Section Chief, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2016 - 2019
Other Appointments/Responsibilities
Chair, St. Luke's Sugar Land Hospital Ethics Committee, Sugar Land, TX, 2013 - 2020
Member, CHI St. Luke's Health Hospital Sugar Land Peer Review, Sugar Land, TX, 2012 - 2013
Chair, Tumor Board for MD Anderson Cancer Center/CHI St. Luke's Health Hospital Sugar Land, Sugar Land, TX, 2011 - 2013
Institutional Committee Activities
Member At-Large, Executive Committee of Executive Staff, 2022 - Present
Physician Representative, REACH Executive Committee, 2022 - Present
Physician Representative, Thoracic Service Line Scheduling Solution- Leadership committee, 2021 - Present
Physician Representative, HAL New Department Work Group, 2021 - 2022
Physician Representative, Faculty Appeals Committee, 2020 - Present
Medical Practice Superintendent, HAL Integration Task Force - Lung Service Line, 2020 - Present
Physician Representative, HAL Research Expansion Initiative, 2019 - Present
Physician Representative, Ambulatory Informatics Committee, 2017 - 2019
Physician Representative, Medical Practice Committee, 2010 - 2012
Honors & Awards
| Top 1% Provider National Ranking, MD Anderson Cancer Center | |
| Top 10% Provider National Ranking, MD Anderson Cancer Center | |
| Melvin L. Samuels Award, MDACC Division of Cancer Medicine |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Wang, T, Navenot, JM, Rafail, S, Kurtis, C, Carroll, M, Van Kerckhoven, M, Van Rossom, S, Schats, K, Avraam, K, Broad, R, Howe, K, Liddle, A, Clayton, A, Wang, R, Quinn, LL, Sanderson, JP, McAlpine, C, Carozza, C, Pimpinella, E, Hsu, SH, Brophy, F, Elefant, E, Bayer, P, Williams, D, Butler, M, Clarke, JM, Gainor, J, Govindan, R, Moreno, V, Johnson, M, Tu, J, Hong, DS, Blumenschein, GR. Identifying MAGE-A4-positive Tumors for TCR T Cell Therapies in HLA-A∗02-eligible Patients. Molecular Therapy Methods and Clinical Development 32(2), 2024. PMID: 38872830.
- Wang, K, Du, R, Myall, NJ, Lewis, WE, Uy, N, Hong, L, Skoulidis, F, Byers, LA, Tsao, A, Cascone, T, Pozadzides, J, Tu, J, Vailati Negrao, M, Gibbons, DL, Park, K, Rinsurongkawong, W, Lee, JJ, Gandara, D, Behl, D, Shu, CA, Riess, JW, Baik, C, Wakelee, HA, Vaporciyan, AA, Heymach, JV, Zhang, J, Le, X. Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC. Journal of Thoracic Oncology 19(3):500-506, 2024. PMID: 38012986.
- Tu J, Altan M. Safety, Tolerability, and Clinical Activity of Selinexor in Combination with Pembrolizumab in Treatment of Metastatic Non-small Cell Lung Cancer. Cancer 129(17):2685-2693, 2023. PMID: 37129197.
- Diaz, EM, Tu, J, Diaz Jr, EM, Antonoff, MB. Lung Cancer Screening in Head and Neck Cancer Patients. Annals of Thoracic Surgery 117(2):305-309, 2023. PMID: 36940898.
- J Wang, Tu J. Severe Radiation-induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC. JTO Clin Res Rep 3(9), 2022. PMID: 36089921.
- Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Distinct Molecular and Immune Hallmarks of Inflammatory Arthritis Induced by Immune Checkpoint Inhibitors for Cancer Therapy. Nat Commun 13(1):1970, 2022. e-Pub 2022. PMID: 35413951.
- Ning MS, Dean MK, Taylor KA, Arzu I, Fleming ND, Mutyala N, Suresh P, Lewis MA, Tu J, Hassid VJ, Joe T, Byler C, Bloom ES, Shah S. Evaluation and Improvement of Bottlenecking in a Multidisciplinary Oncology Clinic: An Electronic Medical Record Intervention. Cureus 11(5):e4583, 2019. e-Pub 2019. PMID: 31309008.
Other Articles
- Kim, ST, Chu, Y, Misoi, MW, Suarez-Almazor, M, Tayar, JH, Lu, H, Buni, M, Kramer, J, Rodriguez, E, Hussain, Z, Neelapu, SS, Wang, RJ, Shah, AY, Tannir, NM, Campbell, M, Gibbons, DL, Cascone, T, Lu, C, Blumenschein, GR, Altan, M, Lim, B, Valero, V, Loghin, ME, Tu, J, Westin, SN, Naing, A, Garcia-Manero, G, Hassan, NA, Tawbi, H, Hwu, P, Oliva, IC, Davies, MA, Patel, SP, Zou, J, Futreal, A, Diab, A, Wang, L, Nurieva, R Distinct Molecular and Immune Hallmarks of Inflammatory Arthritis Induced by Immune Checkpoint Inhibitors for Cancer Therapy (Nature Communications, (2022), 13, 1, (1970), 10.1038/s41467-022-29539-3). Nature Commun 15(1), 2024. PMID: 38965214.
- Rogers JE, Mizrahi JD, Shroff RT, Nelson DA, Tu J, Javle MM, Wolff RA, Pant S Dose-modified Gemcitabine plus Nab-paclitaxel Front-line in Advanced Pancreatic Ductal Adenocarcinoma with Baseline Hyperbilirubinemia. Journal of Gastrointestinal Oncology 11(1):55-60, 2019. PMID: 32175105.
- Mohammad Z, Mitchell KG, Nelson DB, Robb C, Jreissaty C, Tu J, Vaporciyan AA, Sepesi B, Antonoff MB Lung Cancer Patient Perceptions of the Value of an Outreach Thoracic Surgical Clinic. Ann Thorac Surg 108(2):358-362, 2019. PMID: 30928553.
- Mutayala N, Mutayala R, Lewis M, Tu J, Taylor K, Desai S, Buck S, Reed V, and Shah S Describing the Use of a Cost-Effective Online Tool to Qualify the Geographic Location of Patients Served by an Outpatient Oncology Center. Journal of Cancer Prevention and Current Research 6(2):None, 2016. PMID: None.
- Tu JC, Tsao AS, Koczywas M, Riess JW, Tanvetyanon T, Ma B, Ming-Hui H, Zhao Y, Redman M, Edelman M, Gandara D, Kelly K, Gray J A Randomized Phase II Trial of Carboplatin-Paclitaxel with and without Ramucirumab in Patients with Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma. J Thorac Oncol None(None):None. PMID: None.
- Tu J, Le X, Patel J, Shum E, Baik C, Sanborn R, Shu C, Kim C, Fidler M, Hall R, Hanna N, Elamin Y, Blumenschein G, Zhang J, Gibbons D, Gay C, Mohindra N, Chae Y, Boumber Y, Sabari J, Santana-Davila R, Rogosin S, Herzberg B, Creelan B, Tanvetvanon T, Pellini B, Heeke S, Hernandez M, Gray J, Saltos A, Heymach J A Multi-Centre Open-label Randomized Phase II Study of Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Metastatic NSCLC (RAMOSE trial). J Clin Oncol None(None):None. PMID: None.
Patient Reviews
CV information above last modified November 18, 2024